...
首页> 外文期刊>AIDS >High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.
【24h】

High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.

机译:经HIV-1阳性孕妇经胎盘转移后,新生儿raltegravir的浓度较高。

获取原文
获取原文并翻译 | 示例
           

摘要

Raltegravir, an integrase inhibitor, used in the treatment of triple class resistant HIV-1, causes rapid reduction in HIV-1 viral load and is usually well tolerated. Principally metabolized by UGTIAl-mediated glucuronidation, it neither inhibits cytochrome P450 (CYP450) enzymes nor induces CYP3A4, giving it a favourable drug interaction profile [1-3]. These features make raltegravir a useful option for pregnant women who present late or have drug-resistant HIV-1. Little is known about human transplacental transfer of raltegravir, neonatal pharmaco-kinetics and safety.
机译:Raltegravir是一种整合酶抑制剂,用于治疗三级耐药HIV-1,可迅速降低HIV-1病毒载量,并且通常具有良好的耐受性。它主要通过UGTIAl介导的葡糖醛酸糖化作用进行代谢,既不抑制细胞色素P450(CYP450)酶,也不诱导CYP3A4,从而使其具有良好的药物相互作用特征[1-3]。这些功能使raltegravir成为迟发或耐药HIV-1孕妇的有用选择。关于人经胎盘转移的raltegravir,新生儿药代动力学和安全性知之甚少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号